Development of Autophagy Signature-Based Prognostic Nomogram for Refined Glioma Survival Prognostication

Table 1

The clinical baseline table of the GEO and TCGA cohort.

	GEO cohort			TCGA cohort
	Age (years)	Median (50.34)			Median (46.64)
		43	19.5%		95	14.4%
		178	80.5%		565	85.6%
Gender	Male	153	69.2%	Male	380	57.6%
	Female	68	30.8%	Female	280	42.4%
Grade	LGG	93	42.1%	LGG	505	76.5%
	GBM	128	57.9%	GBM	155	23.5%
IDH1 mutation	Wild type	140	63.4%	Wild type	261	39.6%
	Mutant	81	36.7%	Mutant	399	60.5%
Chemotherapy	Yes	84	38.0%	Yes	459	69.6%
	No	137	62.0%	No	201	30.5%
Radiotherapy	Yes	154	69.7%	Yes	478	72.4%
	No	67	30.3%	No	182	27.6%
Overall survival (months)		100	45.3%		181	27.4%
		57	25.8%		297	45.0%
		22	10.0%		105	15.9%
		30	13.6%		59	8.9%
		12	5.4%		18	2.7%